EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer

Shini Liu, Peng Deng, Zhaoliang Yu, Jing Han Hong, Jiuping Gao, Yulin Huang, Rong Xiao, Jiaxin Yin, Xian Zeng, Yichen Sun, Peili Wang, Ruizi Geng und 10 weitere

Advanced Science · 2024-12 · 11 (45)

DOI: 10.1002/advs.202403782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.10.2024. Verfasst von Shini Liu und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Piperazines, Cell Cycle Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Guangzhou Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly (ADP‐ribose) Polymerase inhibitors (PARPi) have demonstrated remarkable clinical efficacy in treating ovarian cancer (OV) with BRCA1/2 mutations. However, drug resistance inevitably limits their clinical applications and there is an urgent need for improved therapeutic strategies to enhance the clinical utility of PARPi, such as Olaparib. Here, compelling evidence indicates that sensitivity of PARPi is associated with cell cycle dysfunction. Through high‐throughput drug screening with a cell cycle kinase inhibitor library, XL413, a potent cell division cycle 7 (CDC7) inhibitor, is identified which can synergistically enhance the anti‐tumor efficacy of Olaparib. Mechanistically, the combined administration of XL413 and Olaparib demonstrates considerable DNA damage and DNA replication stress, leading to increased sensitivity to Olaparib. Additionally, a robust type‐I interferon response is triggered through the induction of the cGAS/STING signaling pathway. Using murine syngeneic tumor models, the combination treatment further demonstrates enhanced antitumor immunity, resulting in tumor regression. Collectively, this study presents an effective treatment strategy for patients with advanced OV by combining CDC7 inhibitors (CDC7i) and PARPi, offering a promising therapeutic approach for patients with limited response to PARPi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsPiperazinesCell Cycle ProteinsPhthalazinesFemaleAnimalsMiceHumansCell Line, TumorDisease Models, AnimalProtein Serine-Threonine KinasesDrug SynergismAntineoplastic Agents

Stichwörter der Autor:innen

CDC7 inhibitorPARP inhibitor resistanceimmune activationovarian cancertarget therapy

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsCDC7 protein, humanolaparibPiperazinesCell Cycle ProteinsPhthalazinesProtein Serine-Threonine KinasesAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
  • Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Southern Medical University, Guangzhou, Guangdong, 510080, P. R. China.
  • Biotherapy Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, P. R. China.
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510655, P. R. China.
  • Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, 169857, Singapore.
  • Department of Laboratory Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, P. R. China.

ORCID-Profile: Jing Tan

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Guangzhou Basic and Applied Basic Research Foundation
  • Guangdong Basic and Applied Basic Research Foundation
  • China Postdoctoral Science Foundation
  • Guangdong Innovative and Entrepreneurial Research Team Program

Zitieren

APA

Liu, S., Deng, P., Yu, Z., Hong, J. H., Gao, J., Huang, Y., Xiao, R., Yin, J., Zeng, X., Sun, Y., Wang, P., Geng, R., Chan, J. Y., Guan, P., Yu, Q., Teh, B. T., Jiang, Q., Xia, X., Xiong, Y., …, & Tan, J. (2024). CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer. Advanced Science, 11(45). https://doi.org/10.1002/advs.202403782

Vancouver

Liu S, Deng P, Yu Z, Hong JH, Gao J, Huang Y, et al. CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer. Advanced Science. 2024;11(45). doi:10.1002/advs.202403782

BibTeX
@article{Liu2024,
  author = {Liu, Shini and Deng, Peng and Yu, Zhaoliang and Hong, Jing Han and Gao, Jiuping and Huang, Yulin and Xiao, Rong and Yin, Jiaxin and Zeng, Xian and Sun, Yichen and Wang, Peili and Geng, Ruizi and Chan, Jason Yongsheng and Guan, Peiyong and Yu, Qiang and Teh, Bin-Tean and Jiang, Qingping and Xia, Xiaojun and Xiong, Ying and Chen, Jianfeng and Huo, Yongliang and Tan, Jing},
  title = {CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {45},
  doi = {10.1002/advs.202403782}
}
Kostenlos starten →